8 news items
Canaccord Genuity Maintains Buy on Ocuphire Pharma, Lowers Price Target to $18
OCUP
13 May 24
Canaccord Genuity analyst John Newman maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target from $22 to $18.
HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
OCUP
13 May 24
HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price target.
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
OCUP
VTRS
10 May 24
the efficacy of APX3330 in slowing DR progression on the target population of the planned Phase 2/3 study, and the FDA agreed upon registration endpoint of a 3
Ocuphire Pharma Announces First Patient Enrolled In LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) For The Treatment Of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
OCUP
11 Apr 24
themselves grappling with these low light or night-time vision challenges, for which there has been no specific, targeted treatment available
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
OCUP
11 Apr 24
challenges, for which there has been no specific, targeted treatment available. If approved, PS offers the potential to enhance visual performance in low
s04xj6b88 46a4hy0gk1vduv9q78zk
DSGN
FTCI
OCUP
26 Mar 24
and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying
2duvj0zsvdp02yhlfsmo8ejccs 3jpvkes0s2u95u5fupl
OCUP
20 Mar 24
Alliance Global Partners analyst James Molloy maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target from $24 to $20.
y7ljwlgm86x0hpujhdllnj7csvwmjbgesg5hgjlnr2jdf 0rdmv7
OCUP
11 Mar 24
HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price target.
- Prev
- 1
- Next